Amicus Therapeutics, Inc.
Amicus Therapeutics focuses on rare disease medicines. It has commercial product Galafold for Fabry disease treatment. Pombiliti + Opfolda treats late onset diseases. The company collaborates with University of Pennsylvania and GlaxoSmithKline. Founded in 2002, its headquartered in Princeton, New Jersey.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (5.96) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (7.30%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 51.9 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 6.0 |